Nektar Therapeutics (NASDAQ:NKTR) has 215 institutional investors that have filed 13F reports for the period ending March 2026.
| Owner Name | Date | Shares Held | Change (QoQ) | Change (%) | Value (USD) |
|---|---|---|---|---|---|
| FMR LLC | 31 Mar, 2026 | 4,303,188 | 4,202,059 | 4,155.15% | $309,614,403.00 |
| BVF INC/IL | 31 Mar, 2026 | 2,559,595 | 1,000,000 | 64.12% | $184,162,860.00 |
| Two Seas Capital LP | 31 Mar, 2026 | 1,959,178 | 1,213,993 | 162.91% | $140,962,857.00 |
| VANGUARD CAPITAL MANAGEMENT LLC | 31 Mar, 2026 | 1,197,055 | 1,197,055 | 0.00% | $86,128,107.00 |
| TWO SIGMA INVESTMENTS, LP | 31 Mar, 2026 | 930,741 | 457,727 | 96.77% | $66,966,815.00 |
| BlackRock, Inc. | 31 Mar, 2026 | 692,650 | 47,043 | 7.29% | $49,836,168.00 |
| Morgan Stanley | 31 Mar, 2026 | 659,387 | 92,966 | 16.41% | $47,442,895.00 |
| ARMISTICE CAPITAL, LLC | 31 Mar, 2026 | 578,000 | -18,000 | -3.02% | $41,587,100.00 |
| Invesco Ltd. | 31 Mar, 2026 | 567,458 | 99,299 | 21.21% | $40,828,603.00 |
| CITADEL ADVISORS LLC | 31 Mar, 2026 | 513,531 | 203,754 | 65.77% | $36,948,555.00 |
| Sofinnova Investments, Inc. | 31 Mar, 2026 | 509,546 | 70,916 | 16.17% | $36,661,835.00 |
| Woodline Partners LP | 31 Mar, 2026 | 415,335 | 311,335 | 299.36% | $29,883,353.00 |
| LORD, ABBETT & CO. LLC | 31 Mar, 2026 | 405,080 | 405,080 | 0.00% | $29,146.00 |
| MILLENNIUM MANAGEMENT LLC | 31 Mar, 2026 | 404,277 | -49,798 | -10.97% | $29,087,730.00 |
| EMERALD ADVISERS, LLC | 31 Mar, 2026 | 394,604 | 10,262 | 2.67% | $28,391,758.00 |
| Qube Research & Technologies Ltd | 31 Mar, 2026 | 390,675 | 66,760 | 20.61% | $28,109,066.00 |
| GEODE CAPITAL MANAGEMENT, LLC | 31 Mar, 2026 | 346,795 | 92,434 | 36.34% | $24,961,900.00 |
| UBS Group AG | 31 Mar, 2026 | 320,172 | 32,611 | 11.34% | $23,036,375.00 |
| GREAT POINT PARTNERS LLC | 31 Mar, 2026 | 316,453 | 105,721 | 50.17% | $22,768,793.00 |
| Vestal Point Capital, LP | 31 Mar, 2026 | 285,000 | 285,000 | 0.00% | $20,505,750.00 |